Patient-reported outcomes from the phase 3 lidERA trial show preserved functioning and less frequent joint pain with giredestrant vs standard endocrine therapy.
|Articles|December 29, 2011
- December 2011
- Volume 12
- Issue 12
New FDA-Approved Oncology Drugs and Indications, 2011
Author(s)Onclive Team
This chart lists the new FDA-approved oncology drugs of 2011 and indications.
Advertisement
The FDA approved more new oncology drugs in 2011 than it has in a single year in more than a decade, thanks in part to priority review and streamlined evaluation procedures. While this is good news for patients, oncology and hematology specialists must tackle the challenges posed by integrating new therapies into treatment plans.
The chart below lists the new FDA-approved oncology drugs of 2011 and indications.
Chart Key:
*As of December 1, 2011 | Sources: FDA news releases, Drugs@FDA Website, prescribing information for individual drugs
a Drug approved for the first time
b New indication or formulation for previously approved brand-name drug or agent
Articles in this issue
almost 15 years ago
Study Supports Smaller Margins in Excising Thicker Melanomasalmost 15 years ago
Hematologic Congress Spotlights Major Issues, Emerging Researchalmost 15 years ago
Minimally Invasive Surgeries Retain Place in Treatment Planalmost 15 years ago
FISH Testing Guides Treatment of CLL: New Drugs on Horizonalmost 15 years ago
NICE's Reluctance to Back Yervoy Turns on Cost-Benefit Perceptionsalmost 15 years ago
Radium-223 Properties Conducive to mCRPC Carealmost 15 years ago
Statins linked to lower risk of prostate cancer mortality in middle-aged menalmost 15 years ago
Avastin Increases PFS in Patients With Ovarian Canceralmost 15 years ago
The Year's New Drugs: Integrating Advances of 2011 Into Treatment Plansalmost 15 years ago
Overcoming Resistance to Endocrine TherapiesAdvertisement
Related to this article
Exploratory subgroup analyses of the phase 2 DOVACC trial suggested a possible signal with the triplet in HRD-negative and PARP inhibitor–naive disease.
Fadi Haddad, MD, discusses TKI adherence barriers, adverse effect management, and the role of alternative TKI formulations in CML.
With multiple ADCs now available for use in gynecologic cancers, treatment decision-making incorporates biomarker nuances and raises sequencing questions.
Experts in gynecologic oncology overview top research being presented at the 2026 ESMO Congress.
Omar Castaneda Puglianini, MD, discusses earlier CAR T-cell therapy use, sequencing with bispecific antibodies, and access barriers in multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
Adjuvant Giredestrant Preserves QOL With Sustained Tolerability in ER+, HER2– Early Breast Cancer
2
Sacituzumab Govitecan Triplet Elicits Durable Responses in Treatment-Naive Metastatic Urothelial Cancer
3
Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves ctDNA Clearance in Cisplatin-Eligible MIBC
4
Ad Hoc Analysis Supports Contributions of Both Enfortumab Vedotin and Pembrolizumab in Cisplatin-Ineligible MIBC
5